Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

This publication has 30 references indexed in Scilit:

• Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers
  Clinical Therapeutics, 2006
• Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study
  Diabetes, Obesity and Metabolism, 2005
• Incretin hormones and insulin sensitivity
  Trends in Endocrinology & Metabolism, 2005
• GLP-1 Receptor Agonists and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes
  Hormone and Metabolic Research, 2004
• Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?
  Expert Opinion on Investigational Drugs, 2004
• Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
  American Journal of Physiology-Endocrinology and Metabolism, 2004
• Standards of Medical Care for Patients With Diabetes Mellitus
  Diabetes Care, 2003
• Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
  JAMA, 2001
• Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.
  Diabetes Care, 2000
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
  The Lancet, 1998